A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

Exclusion Criteria

• •Patients with a significant disease or condition other than IPF, which in the opinion of the investigator, may put the patient at risk because of participation, interfere with study procedures, or cause concern regarding the patient's ability to participate in the study
• •Acute IPF exacerbation within 1 month prior to Visit 1 and/or during the screening period (investigator-determined).
• •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.5 x ULN or total Bilirubin \>1.5 x upper limit of normal (ULN) at Visit 1
• •Patients with underlying liver cirrhosis (Child Pugh C hepatic impairment)
• •Cardiovascular diseases, any of the following:
• •* Severe hypertension (uncontrolled under treatment ≥160/100 mmHg at multiple occasions) within 3 months of Visit 1
• •* Myocardial infarction, stroke or transient ischemic attack within 6 months of Visit 1
• •* Unstable cardiac angina within 6 months of Visit 1
• •Chronic kidney disease with estimated glomerular filtration rate (eGFR) less than 90 ml/min/1.73 m\^2 at Visit 1/screening (Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula or Japanese version of CKD-EPI for Japanese patients)
• •Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
• •Relevant chronic or acute infections including but not limited to human immunodeficiency virus (HIV) and viral hepatitis